Skip to main content
Equibles
NVO logo

NVO · Novo Nordisk A S

Track NVO — free

Use NVO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NVO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$45.89 -0.83 (-1.78%) At close · Aug 14
Market Cap
$201.05B
Shares
4.38B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$45.89 Open$46.90 Day$45.75–47.05 52W close$35.29–63.98 Avg vol 30d11.6M Short int29.4M · 0.7% float · 2.9d Short vol46% Last earningsDec 31, 2025 DataSep 2023–Aug 2026

Raw chart and full-history price indicators begin at the captured split on Sep 20, 2023; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Research

our published analysis of this company

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −1%
below
Price vs 50-day avg −3%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 37%
mid-range
Momentum
relative strength
Neutral
1-month return −9%
trailing
6-month return +16%
trailing
YTD return −10%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $47 › 200d $47 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +214 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.67% of float · ▼ -5.4% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,337 holders — mid 3-yr range
Squeeze score 37
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −45%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2024
Top-line growth · full-year 19% – 27%
Operating profit growth · full-year 22% – 30%
Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
Sales growth · 2025 8% – 11%
Operating profit growth · 2025 4% – 7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−1% Neutral
Price vs 50-day avg
−3% Neutral
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
37% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $47 › 200d $47 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +214 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.67% of float · ▼ -5.4% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,337 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $35 Now $46 · 37% Range high $64
vs 200-day avg -1% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NVO
Novo Nordisk A S
this stock
$201.05B -9.8% — — 0.7%
LLY
ELI LILLY & Co
 $1.11T +9.8% +44.7% 39.6 1.0%
JNJ
Johnson & Johnson
 $627.42B +25.8% +6.0% 30.2 1.1%
ABBV
AbbVie Inc.
 $442.24B +9.2% +8.6% 70.7 1.3%
MRK
Merck & Co., Inc.
 $335.14B +29.1% +1.3% 108.7 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,337
% held
12.2%
Net QoQ
+127.0M sh
Top holder
XXEC, Inc.
Held Float
View
Held by Funds
Fund positions
155
View
Short & Settlement
Short Interest Falling
Shares short
29.4M
Days to cover
2.9d
Change
-1.7M sh
View
Short Volume
Short vol %
46%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
27.4K
Value
$1.4M
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
49.7%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$15.0K–$50.0K
Traded
Mar 30, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 10, 2026
This year
53
View
Proposed Sales
Value
$2.0M
Shares
921.9K
Filed
May 30, 2025
View
Earnings & Events
Earnings Calls
Last call
Dec 31, 2025
View
Investor Relations
Upcoming events
2
View

Performance

Raw-price comparisons begin at the captured split on Sep 20, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
NVO -2.9% -8.8% +15.8% -2.5% -9.8%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -3.3% -13.3% +2.0% -6.5% -23.7%

Capital returns

Latest dividend
$1.275 / share · ex Mar 30, 2026
Declared · upcoming
$0.5786 / share · ex Aug 17, 2026
Raised 118.3%
Paid (TTM)
$1.859 / share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 353278 CUSIP 670100205 13F (30d) 1204 filings 1158 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)